Vancouver, BC – A genomics research project is focused on identifying new inhibitors for drug targets that will lead to the creation of novel classes of antimicrobials against Gram negative bacteria and biodefense agents.
Indel Therapeutics Inc. (www.indelrx.com) announced today that it is the industry partner for a new this research project entitled, “Combating drug-resistant pathogens”.
As part of this research project, Genome BC (www.genomebc.ca)awarded funding to Dr. Neil Reiner of the University of British Columbia, the Company’s scientific founder and Chief Scientific Officer, and Fiona Brinkman of Simon Fraser University, through its peer-reviewed Proof-of-Concept program. Drs. Reiner and Brinkman, along with industry partner Indel Therapeutics, will work to identify novel drug targets and therapeutics for antibiotic-resistant nosocomial pathogens (hospital-acquired infections) that address the ongoing issue of multidrug-resistant (MDR) bacterial pathogens.
Genome British Columbia is a catalyst for the life sciences cluster on Canada’s West Coast, and manages a cumulative portfolio of over $550M in research projects and science and technology platforms.
Indel Theraputics is a biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance,
“We could not be more pleased that Genome BC recognizes both the importance and potential of the Indel Antimicrobial Targeting Approach,” said Dr. Neil Reiner. “This funding will help identify novel antibiotics to address the global crisis of multidrug-resistant Gram negative infections, an area where there are virtually no new drugs in development.”